The global molecular cytogenetics market size is expected to reach USD 3. 8 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a 10.4% CAGR during the forecast period. Mapping of human genome, coupled with continuous technological advancements in cytogenetic techniques, has enabled researchers to gain insight into the disease-causing mechanism at a genomic as well as the cellular level. Development in molecular technologies has helped in bridging the gap between molecular biology and cytogenetics, which was not possible using conventional cytogenetic techniques.
There is a continuous growth in awareness, and consequent adoption, of genetic tests for disease prognosis. These tests also help in designing further treatment regimes for widespread chromosomal abnormalities. This is sure to boost the market growth.
Incorporation of high throughput sequencers in the cytogenetic analysis is expected to significantly enhance the market growth in the coming years. A number of researchers and scientists have begun converging cytogenetics laboratories with NGS as they complement each other. Hence, with an exponential decline in sequencing prices, this market is expected to grow at a lucrative pace.
However, ambiguous regulatory and reimbursement scenario in certain regions pertaining to the implementation of genetic tests is expected to hamper the adoption of molecular cytogenetic techniques to a certain extent.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the report suggest:
Oncology held the largest share in the market in 2016 owing to the ability of CGH technology to facilitate in-depth studies for cancer etiology
The use of molecular cytogenetics in personalized medicine development is expected to grow lucratively during the forecast period. This is majorly due to a continuous shift toward targeted therapies for effective disease management
The requirement of consumables in the entire cytogenetics process is attributive for the largest share of this product category
Ongoing research projects for developing a treatment regimen of different genetic conditions have allowed clinical and research laboratories to gain a significant share in the market
Pharmaceutical and biotech companies are expected to be a key source of revenue in the coming years. This is mainly because a number of pharmaceutical companies have expanded their business in the field of personalized medicine
Illumina, Inc.; Agilent Technologies, Inc.; Abbott; Bio-Rad Laboratories, Inc.; and Oxford Gene Technology are some prominent companies in the market. They are involved in the development and commercialization of cytogenetics techniques
Some major service providers are Weill Cornell Medicine; WiCell Research Institute, Inc.; ARUP Laboratories; and Integrated Systems Engineering S.r.l.
Grand View Research has segmented the global molecular cytogenetics market on the basis of application, product, end use, technology, and region:
Molecular Cytogenetics Application Outlook (Revenue, USD Million, 2014 - 2025)
Molecular Cytogenetics Product Outlook (Revenue, USD Million, 2014 - 2025)
Software & Services
Molecular Cytogenetics End-use Outlook (Revenue, USD Million, 2014 - 2025)
Clinical & Research Laboratories
Hospitals & Pathology Laboratories
Academic Research Institutes
Pharmaceutical and Biotechnology Companies
Molecular Cytogenetics Technology Outlook (Revenue, USD Million, 2014 - 2025)
Comparative Genomic Hybridization
Array-based comparative genomic hybridization
Standard comparative genomic hybridization
Fluorescence In Situ Hybridization (FISH)
Molecular Cytogenetics Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East & Africa
This report has a service guarantee. We stand by our report quality.
Your transaction & personal information is safe and secure.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
Avail customized purchase options to meet your research needs:
"The quality of research they have done for us has been excellent..."